The precision of PSMA PET/CT in detecting prostate cancer recurrence at lower PSA levels underscores its potential to significantly inform treatment decisions, particularly in the context of ultrasensitive PSA monitoring. The gene discussed is FOLH1; the disease is Familial prostate cancer.